CA2876252A1 - Biomarkers for prostate cancer - Google Patents
Biomarkers for prostate cancer Download PDFInfo
- Publication number
- CA2876252A1 CA2876252A1 CA2876252A CA2876252A CA2876252A1 CA 2876252 A1 CA2876252 A1 CA 2876252A1 CA 2876252 A CA2876252 A CA 2876252A CA 2876252 A CA2876252 A CA 2876252A CA 2876252 A1 CA2876252 A1 CA 2876252A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- nucleotide sequence
- st6galnac3
- hapln3
- gas6
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Primary Health Care (AREA)
- Databases & Information Systems (AREA)
- Data Mining & Analysis (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201270326 | 2012-06-14 | ||
| DKPA201270326 | 2012-06-14 | ||
| PCT/DK2013/050196 WO2013185779A2 (en) | 2012-06-14 | 2013-06-14 | Biomarkers for prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2876252A1 true CA2876252A1 (en) | 2013-12-19 |
Family
ID=48740787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2876252A Pending CA2876252A1 (en) | 2012-06-14 | 2013-06-14 | Biomarkers for prostate cancer |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10106854B2 (https=) |
| EP (1) | EP2861759B1 (https=) |
| JP (1) | JP6242388B2 (https=) |
| AU (1) | AU2013275761B2 (https=) |
| CA (1) | CA2876252A1 (https=) |
| WO (1) | WO2013185779A2 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2859645T3 (es) | 2013-03-14 | 2021-10-04 | Mayo Found Medical Education & Res | Detección de neoplasia |
| EP3037545A1 (en) * | 2014-12-23 | 2016-06-29 | The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin | A DNA-methylation test for prostate cancer |
| CN107532124B (zh) | 2015-03-27 | 2022-08-09 | 精密科学公司 | 检测食管疾病 |
| CN108138235B (zh) | 2015-08-31 | 2022-04-15 | 梅约医药教育及研究基金会 | 检测胃肿瘤 |
| CN106480169B (zh) * | 2015-09-01 | 2019-10-08 | 杨小丽 | 人aqp10和sox17基因甲基化位点的检测和应用 |
| CN110431241B (zh) | 2017-02-28 | 2024-04-19 | 梅约医学教育与研究基金会 | 检测前列腺癌 |
| GB201816820D0 (en) | 2018-10-16 | 2018-11-28 | Univ York | Diagnostic method |
| EP3880846B1 (en) | 2018-11-13 | 2024-08-28 | Bracco Imaging SPA | Gene signatures for the prediction of prostate cancer recurrence |
| CN109468381B (zh) * | 2018-11-19 | 2022-11-25 | 兰州市第一人民医院 | 用于宫颈癌筛查的甲基化位点及其检测引物 |
| EP3999662A1 (en) * | 2019-07-19 | 2022-05-25 | Vilnius University | Characterization of prostate cancer using dna methylation assay system |
| CN113122636A (zh) * | 2020-01-14 | 2021-07-16 | 上海鹍远生物技术有限公司 | 检测dna甲基化的试剂及用途 |
| EP4146678A4 (en) * | 2020-05-04 | 2025-08-27 | Mayo Found Medical Education & Res | DETECTION OF PANCREATIC NEUROENDOCRINE TUMORS |
| WO2021226110A1 (en) * | 2020-05-05 | 2021-11-11 | The Board Of Trustees Of The Leland Stanford Junior University | Cell-free dna biomarkers and their use in diagnosis, monitoring response to therapy, and selection of therapy for prostate cancer |
| CN118685523B (zh) * | 2024-08-26 | 2024-11-15 | 湖南宏雅基因技术有限公司 | 一种用于前列腺癌检测的生物标志物组合、引物探针组合物及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5786146A (en) | 1996-06-03 | 1998-07-28 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
| US6605432B1 (en) | 1999-02-05 | 2003-08-12 | Curators Of The University Of Missouri | High-throughput methods for detecting DNA methylation |
| US20020137086A1 (en) * | 2001-03-01 | 2002-09-26 | Alexander Olek | Method for the development of gene panels for diagnostic and therapeutic purposes based on the expression and methylation status of the genes |
| US20100297067A1 (en) * | 2007-05-14 | 2010-11-25 | The Johns Hopkins University | Methylation markers for prostate cancer and methods of use |
| WO2010017301A1 (en) * | 2008-08-05 | 2010-02-11 | Veridex, Llc | Prostate cancer methylation assay |
| KR20110111462A (ko) * | 2009-01-07 | 2011-10-11 | 미리어드 제네틱스, 인크. | 암 바이오마커 |
| US20100303795A1 (en) | 2009-05-27 | 2010-12-02 | Soerensen Karina Dalsgaard | Marker of prostate cancer |
| WO2011027310A1 (en) * | 2009-09-03 | 2011-03-10 | Koninklijke Philips Electronics N.V. | Novel tumor markers |
| WO2011037936A2 (en) * | 2009-09-24 | 2011-03-31 | Oregon Health & Science University | Detection of dna methylation of tal1, erg and/or cd40 to diagnose prostate cancer |
| WO2011044902A1 (en) | 2009-10-13 | 2011-04-21 | Aarhus Universitet | Tff3 hypomethylation as a novel biomarker for prostate cancer |
| US20110223180A1 (en) * | 2010-03-11 | 2011-09-15 | Aldape Kenneth D | Methods and compositions related to a multi-methylation assay to predict patient outcome |
| WO2012138609A2 (en) * | 2011-04-04 | 2012-10-11 | The Board Of Trustees Of The Leland Stanford Junior University | Methylation biomarkers for diagnosis of prostate cancer |
-
2013
- 2013-06-14 US US14/407,541 patent/US10106854B2/en active Active
- 2013-06-14 JP JP2015516469A patent/JP6242388B2/ja active Active
- 2013-06-14 WO PCT/DK2013/050196 patent/WO2013185779A2/en not_active Ceased
- 2013-06-14 AU AU2013275761A patent/AU2013275761B2/en active Active
- 2013-06-14 EP EP13732819.1A patent/EP2861759B1/en active Active
- 2013-06-14 CA CA2876252A patent/CA2876252A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20150152507A1 (en) | 2015-06-04 |
| EP2861759A2 (en) | 2015-04-22 |
| JP6242388B2 (ja) | 2017-12-06 |
| AU2013275761A1 (en) | 2015-01-22 |
| AU2013275761B2 (en) | 2017-09-28 |
| WO2013185779A3 (en) | 2014-02-06 |
| EP2861759B1 (en) | 2025-06-04 |
| JP2015527875A (ja) | 2015-09-24 |
| US10106854B2 (en) | 2018-10-23 |
| WO2013185779A2 (en) | 2013-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10106854B2 (en) | Biomarkers for prostate cancer | |
| Chimonidou et al. | CST6 promoter methylation in circulating cell-free DNA of breast cancer patients | |
| JP2020513795A (ja) | 前立腺癌検出 | |
| US20140094380A1 (en) | Methylation Biomarkers for Diagnosis of Prostate Cancer | |
| US12252747B2 (en) | Unbiased DNA methylation markers define an extensive field defect in histologically normal prostate tissues associated with prostate cancer: new biomarkers for men with prostate cancer | |
| WO2012154979A2 (en) | Method of detecting cancer through generalized loss of stability of epigenetic domains, and compositions thereof | |
| EP2665834A1 (en) | Epigenetic portraits of human breast cancers | |
| CN111440863B (zh) | Kazn基因甲基化检测试剂在制备结直肠癌预后诊断试剂中的应用 | |
| Kim et al. | Can we use methylation markers as diagnostic and prognostic indicators for bladder cancer? | |
| ES3036448T3 (en) | A dna-methylation test for prostate cancer | |
| US20120135877A1 (en) | DNA Methylation Markers For Prostate Cancer Field Defect | |
| US12071672B2 (en) | Unbiased DNA methylation markers define an extensive field defect in histologically normal prostate tissues associated with prostate cancer: new biomarkers for men with prostate cancer | |
| US20090186360A1 (en) | Detection of GSTP1 hypermethylation in prostate cancer | |
| Ross et al. | Identification of differentially methylated regions using streptavidin bisulfite ligand methylation enrichment (SuBLiME), a new method to enrich for methylated DNA prior to deep bisulfite genomic sequencing | |
| US20180179597A1 (en) | Cancer markers | |
| EP2978861B1 (en) | Unbiased dna methylation markers define an extensive field defect in histologically normal prostate tissues associated with prostate cancer: new biomarkers for men with prostate cancer | |
| KR101273569B1 (ko) | 전립선암 특이적 유전자의 메틸화 검출 방법 및 이의 용도 | |
| Leong | Development of epigenetic-based prognostic biomarkers to stratify risk of recurrence in early rectal cancer | |
| WO2009134468A2 (en) | Detecting prostate cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180503 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20240717 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241219 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250120 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250120 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 12TH ANNIV.) - STANDARD Year of fee payment: 12 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250603 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250603 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251029 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251104 |